Catalent to supply the newly approved Exelixis CometriqT (Cabozantinib) in the US market

Somerset, NJ, December 7, 2012 – After a 5 year close partnership with Exelixis during which Catalent has provided analytical, clinical trial supply and manufacturing support for COMETRIQ™ (cabozantinib), Catalent welcomes FDA approval for Exelixis’ novel drug for treatment of progressive, metastatic medullary thyroid cancer (MTC). Catalent will now continue to be the exclusive commercial drug supply partner for the 20 mg and 80 mg capsule dose packs in the United States.

This content was submitted directly to this website by the supplier.

Catalent supports pharmaceutical companies, small and large, to help them accelerate their drug development and bring new treatments to improve patient’s lives.”   Said Scott Houlton, President, Development and Clinical Services of Catalent. “We have worked closely with Exelixis over the past several years on COMETRIQ and are delighted to have reached this key milestone.”

“We have been pleased to partner with Catalent over the last 5 years. Catalent has provided high quality service for analytical testing, manufacturing process development and validation.  This partnership has truly helped advance this important product for cancer patients,” said JoAnn Wilson, Vice President, Chemical, Manufacturing and Control at Exelixis, Inc.

All U.S. COMETRIQ capsule manufacturing and packaging operations will be undertaken at Catalent’s 450,000 sq ft, Kansas City, MO facility, which provides a range of fully integrated support services, from formulation development and analytical testing, to clinical supply services as well as clinical and commercial scale manufacturing and packaging of a variety oral dose forms.

Companies in this article
More in Home